Resumen de Closing in on cancer
Coghlan talks about PD-1 inhibitors. These focus the immune attack on cancer cells rather than on healthy tissue, which means they are more effective and milder than ipi. The biggest boost from the new drugs is that there's a 30% to 40% chance the effects will be durable, for years, not months. In trials so far, nivo and pembro have routinely outperformed both ipi and the best existing chemo- and radiotherapy treatments, often triggering double the rate of tumor shrinkage and patient survival with far milder side effects. One reason the drugs are proving so successful is that remobilizing the immune system allows it to continuously evolve to keep the tumor in check, limiting the ability of the cancer to escape detection and destruction even if it develops hundreds of mutations.
